Trial Profile
A phase 2 study of K-134 in patients with peripheral arterial disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs K 134 (Primary)
- Indications Embolism and thrombosis; Intermittent claudication; Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kowa Pharmaceutical
- 21 Nov 2014 New source identified and integrated (JAPIC Clinical Trials Information; JapicCTI-090869).
- 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
- 16 Nov 2011 New trial record